

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3082721

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PGXHEALTH, LLC	11/29/2010
RECEIVING PARTY DATA	
Name:	TRANSGENOMIC, INC.
Street Address:	12325 EMMET STREET
City:	OMAHA
State/Country:	NEBRASKA
Postal Code:	68164
PROPERTY NUMBERS Total: 22	
Property Type	Number
Application Number:	10048427
Application Number:	10965348
Application Number:	10479225
Application Number:	12880001
Application Number:	09958635
Application Number:	12404772
Application Number:	61285815
Application Number:	12764841
Application Number:	14152557
Application Number:	13350635
Application Number:	10635780
Application Number:	10525360
Application Number:	12221241
Application Number:	12221130
Application Number:	12477506
Application Number:	09583447
Application Number:	10007814
Application Number:	61410735
Application Number:	09791105
Application Number:	10070588
Application Number:	10070587

PATENT

Property Type	Number
Application Number:	10182977

CORRESPONDENCE DATA

Fax Number: (612)339-3061
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 612-373-6900

Email: request@slwip.com

Correspondent Name: SCHWEGMAN LUNDBERG & WOESSNER P.A.

Address Line 1: P.O. BOX 2938

Address Line 4: MINNEAPOLIS, MINNESOTA 55402

ATTORNEY DOCKET NUMBER:	4141.001US1
NAME OF SUBMITTER:	DEBRA E BARTELL
SIGNATURE:	/Debra E. Bartell /
DATE SIGNED:	10/27/2014

Total Attachments: 12

source=4141PGxhealth_assignment_f#page1.tif
source=4141PGxhealth_assignment_f#page2.tif
source=4141PGxhealth_assignment_f#page3.tif
source=4141PGxhealth_assignment_f#page4.tif
source=4141PGxhealth_assignment_f#page5.tif
source=4141PGxhealth_assignment_f#page6.tif
source=4141PGxhealth_assignment_f#page7.tif
source=4141PGxhealth_assignment_f#page8.tif
source=4141PGxhealth_assignment_f#page9.tif
source=4141PGxhealth_assignment_f#page10.tif
source=4141PGxhealth_assignment_f#page11.tif
source=4141PGxhealth_assignment_f#page12.tif

RECORDATION FORM COVER SHEET
PATENTS ONLY

Atty Ref/Docket No.: 4141.001US2

Patent and Trademark Office

To the Director of the U.S. Patent and Trademark Office: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

PGxHealth, LLC

Additional name(s) of conveying party(ies) attached?

[] Yes [X] No

3. Nature of conveyance:

[X] Assignment

[] Merger

[] Security Agreement [] Change of Name

[] Other

Execution Date: November 29, 2010

2. Name and address of receiving party(ies):

Name: Transgenomic, Inc.

Street Address: 12325 Emmet Street

City: Omaha State: NE Zip: 68164

Country: United States of America

Additional name(s) & address(es) attached? [] Yes [X] No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

B. Patent No.(s)

Serial No. 10/965,348

Additional numbers attached? [X] Yes [] No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Janet E. Embretson

Address:

Schwegman Lundberg & Woessner, P.A.

P.O. Box 2938

Minneapolis, MN 55402--0938

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41):\$ 0.00

[] Enclosed

[] Authorized to be charged to deposit account 19-0743

8. Please charge any additional fees or credit any over payments to our Deposit Account No.: 19-0743

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Janet E. Embretson/Reg. No. 39,665

/Janet E. Embretson/ October 24, 2014

Name of Person Signing

Signature

Date

Total number of pages including cover sheet: 0

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks

Mail Stop Assignment Recordation Services

P.O. Box 1450

Alexandria, VA 22313-1450

PATENT
REEL: 034044 FRAME: 0680

Table 1 -

Patent #	Application #	Filing date	SLW matter#	status
	10/048,427		4141.001US1	Abandoned
	10965348		4141.001US2	pending
	10/479,225	Apr 8, 2004	4141.002US1	issued
	PCT/EP2002/006000		4141.002WO1	complete
	12/880,001	Sep 10, 2010	4141.002US2	pending
	09/958,635	Feb 2, 2002	4141.003us1	abandoned
	12/404,772	Mar 16, 2009	4141.003us2	pending
	10/627,253		4141.009US1	abandoned
	11/901,238		4141.009US2	issued
	13/273,856		4141.009US3	abandoned
	13/711,281		4141.009US4	abandoned
	14/276,577		4141.009US5	pending
	61/285,815		4141.012prv	expired
	12/764,841		4141.012US1	issued
	14/152,557		4141.012US2	pending
	PCT/EP2001/000954		4141.013WO1	completed
8,129,112	10/182,977	Jan 24, 2003	4141.013US1	issued
	13/350,635	Jan 13, 2012	4141.013US2	pending
	10/635,780	Aug 5, 2003	4141.014US1	pending
	PCT/EP2003/009356		4141.015WO1	completed
	10/525,360	Aug 22, 2003	4141.015US1	abandoned
	12/221,241	Jul 30, 2008	4141.015US2	pending
	12/221,130	Jul 30, 2008	4141.015US3	abandoned
	12/477,506	Jun 3, 2009	4141.015US4	abandoned
6,645,745	09/583,447	May 30, 2000	4141.023US1	issued
	10/007,814	Nov 9, 2001	4141.023US2	abandoned
	61/410,735	Nov 5, 2010	4141.030PRV	expired
	PCT/US2011/059595	Nov 7, 2011	4141.030WO1	completed
6,723,508	09/791,105	Feb 22, 2001	4141.033US1	issued
	PCT/EP2000/008827	Sep 8, 2000	4141.034WO1	completed
7,122,652	10/070,588	Oct 15, 2002	4141.034US1	issued
	PCT/EP2000/008570		4141.035WO1	completed
7,655,771	10/070,587		4141.035US1	issued
	PCT/EP2001/001456	Feb 9, 2001	4141.038WO1	Complete**

DISCLOSURE SCHEDULE

This disclosure schedule ("*Disclosure Schedule*") is being furnished by PGXHEALTH, LLC, a Delaware limited liability company (the "*Seller*"), CLINICAL DATA, INC., a Delaware corporation (the "*Seller Parent*"), to TRANSGENOMIC, INC., a Delaware corporation (the "*Buyer*") in connection with the execution and delivery of that certain Asset Purchase Agreement dated as of November 29, 2010 (the "*Agreement*"), by and among Seller, Seller Parent and Buyer. Unless the context otherwise requires, all capitalized terms used in this Disclosure Schedule shall have the respective meanings assigned to them in the Agreement.

No reference to or disclosure of any item or other matter in this Disclosure Schedule shall be construed as an admission or indication that such item or other matter is material or that such item or other matter is required to be referred to or disclosed in this Disclosure Schedule. No reference in this Disclosure Schedule to any agreement or document shall be construed as an admission or indication that such agreement or document is enforceable or currently in effect or that there are any obligations remaining to be performed or any rights that may be exercised under such agreement or document. No disclosure in this Disclosure Schedule relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

This Disclosure Schedule and the information and disclosures contained in this Disclosure Schedule are intended only to qualify and limit the representations, warranties and covenants of Company contained in the Agreement and shall not be deemed to expand in any way the scope or effect of any of such representations, warranties or covenants.

Notwithstanding anything to the contrary contained in this Disclosure Schedule or in the Agreement, the information and disclosures contained in each section of this Disclosure Schedule shall be deemed to be disclosed and incorporated by reference in each of the other sections of this Disclosure Schedule as though fully set forth in such other sections (whether or not specific cross-references are made) to the extent that it is readily apparent that such disclosure is applicable to such other section.

The bold-faced headings contained in this Disclosure Schedule are included for convenience only, and are not intended to limit the effect of the disclosures contained in this Disclosure Schedule or to expand the scope of the information required to be disclosed in this Disclosure Schedule.

2. Intellectual Property

Patents

COUNTRY	PATENT / PUBLICATION NUMBER	APPLICATION NUMBER	DATE FILED	TITLE
US		12/764,841	21-Apr-10	Mutations associated with Long QT Syndrome
US		61/285,815	11-Dec-09	Mutations associated with Long QT Syndrome
US	6,645,745	09/583,447	30-May-00	Identification of a new member of the cytochrome P450 3A (CYP3A) gene family: CYP3AX
US	2005/0227249	10965348	14-Oct-04	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
AT	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
BE	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
BG	106362	106362	28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
CA	2,376,666	2,376,666	22-Jan-02	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
CA	2,697,207	2,697,207	23-Mar-10	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
CH	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
DE	EP1232260	60036487908	28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
DK	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
EE	200200049	200049	28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
EP	1232260	9726548	28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
ES	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications

COUNTRY	PATENT / PUBLICATION NUMBER	APPLICATION NUMBER	DATE FILED	TITLE
FR	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
GB	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
HR	20020093	38103020110093	28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
IE	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
IN	224535		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
IT	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
JP	2003510021	2001513989	28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
KR	914188	70012482002	28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
LU	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
MC	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
MX	263302	PAA2002001094	28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
NL	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
NO	20020470	20020470	28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
SE	EP1232260		28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
SG	86239	2002002806	28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
ZA	200773	20020773	28-Jul-00	Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications

COUNTRY	PATENT / PUBLICATION NUMBER	APPLICATION NUMBER	DATE FILED	TITLE
US	7655771	10070587	10-Jul-02	Polymorphisms in the human CYP3A4 and CYP3A7 genes and their use in diagnostics and therapeutic applications
JP	2003509063	2001523796	1-Sep-00	Polymorphisms in the human CYP3A4 and CYP3A7 genes and their use in diagnostics and therapeutic applications
US	2004/0224424	10/182,977	24-Jan-03	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
AT	E333504T1	E333504	30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
CA	2,398,104	2,398,104	30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
CH	EP1276880		30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
DE	60121567T2	601215672	30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
EP	1276880	19468958	30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
ES	2267787		30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
FR	EP1276880		30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
GB	EP1276880		30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
IE	EP1276880		30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications

LEGAL_US_W # 66400296. 1

COUNTRY	PATENT / PUBLICATION NUMBER	APPLICATION NUMBER	DATE FILED	TITLE
IT	EP1276880		30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
JP	2004506405	2001554461	30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
LI	EP1276880		30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
LU	EP1276880		30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
NL	EP1276880		30-Jan-01	Polymorphisms in the human CYP2D6 gene promoter region and their use in diagnostic and therapeutic applications
US	2009/0311696	12404772	16-Mar-09	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
AT	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
BE	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
CH	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
DE	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
DK	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
EP	1272663	19138098	9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications

COUNTRY	PATENT / PUBLICATION NUMBER	APPLICATION NUMBER	DATE FILED	TITLE
ES	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
FI	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
FR	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
GB	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
GR	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
IE	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
IT	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
LI	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
LU	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
MC	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
NL	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
PT	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications

LEGAL_US_W # 66400296. I

COUNTRY	PATENT / PUBLICATION NUMBER	APPLICATION NUMBER	DATE FILED	TITLE
SE	EP1272663		9-Feb-01	Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications
US	6723508	9791105	22-Feb-01	Method for detecting the presence of at least one single allele of a deletion mutant
US	7,122,652	10/070,588	15-Oct-02	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
BE	EP1210462		8-Sep-00	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
CA	2,381,066	2,381,066	4-Mar-02	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
CH	EP1210462		8-Sep-00	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
DE	60037126.3	600371263	8-Sep-00	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
EP	1210462	9585308	8-Sep-00	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
FR	EP1210462		8-Sep-00	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
GB	EP1210462		8-Sep-00	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
IE	EP1210462		8-Sep-00	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
JP	2003509064	2001523797	8-Sep-00	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
LU	EP1210462		8-Sep-00	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
MC	EP1210462		8-Sep-00	Polymorphisms in the human hPXR gene and their use in diagnostic and therapeutic applications
BE	EP1358353		21-Dec-01	Identification of the genetic determinants of the polymorphic CYP3A5 expression
CH	EP1358353		21-Dec-01	Identification of the genetic determinants of the polymorphic CYP3A5 expression

COUNTRY	PATENT / PUBLICATION NUMBER	APPLICATION NUMBER	DATE FILED	TITLE
DE	EP1358353		21-Dec-01	Identification of the genetic determinants of the polymorphic CYP3A5 expression
EP	1358353	19948314	21-Dec-01	Identification of the genetic determinants of the polymorphic CYP3A5 expression
ES	2288173		21-Dec-01	Identification of the genetic determinants of the polymorphic CYP3A5 expression
FR	EP1358353		21-Dec-01	Identification of the genetic determinants of the polymorphic CYP3A5 expression
GB	EP1358353		21-Dec-01	Identification of the genetic determinants of the polymorphic CYP3A5 expression
IE	EP1358353		21-Dec-01	Identification of the genetic determinants of the polymorphic CYP3A5 expression
IT	EP1358353		21-Dec-01	Identification of the genetic determinants of the polymorphic CYP3A5 expression
LU	EP1358353		21-Dec-01	Identification of the genetic determinants of the polymorphic CYP3A5 expression
MC	EP1358353		21-Dec-01	Identification of the genetic determinants of the polymorphic CYP3A5 expression
US	2006/0172291	10/479,225	8-Apr-04	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
BE	EP1397486		31-May-02	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
CH	EP1397486		31-May-02	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
DE	EP1397486		31-May-02	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
EP	1397486	02776511.4	31-May-02	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications

COUNTRY	PATENT / PUBLICATION NUMBER	APPLICATION NUMBER	DATE FILED	TITLE
EP		10170985.5	31-May-02	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
ES	EP1397486		31-May-02	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
FR	EP1397486		31-May-02	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
GB	EP1397486		31-May-02	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
IE	EP1397486		31-May-02	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
IT	EP1397486		31-May-02	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
NL	EP1397486		31-May-02	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
US		12/880,001	10-Sep-10	Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications
US	2009/0144841	11/901,238	20-Dec-07	Polymorphisms in the human gene for the multidrug resistance-associated protein (MRP-1) and their use in diagnostic and therapeutic applications
US	2005/0032070	10/635,780	5-Aug-03	Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
US	2009/0018030	12/221,241	30-Jul-08	Polymorphisms in the human genes for OCT1 and their use in diagnostic and therapeutic applications
EP	1534747	03792418.0	22-Aug-03	Polymorphisms in the human genes for OCT1 and their use in diagnostic and therapeutic applications

COUNTRY	PATENT / PUBLICATION NUMBER	APPLICATION NUMBER	DATE FILED	TITLE
EP		10185649.0	22-Aug-03	Polymorphisms in the human genes for OCT1 and their use in diagnostic and therapeutic applications
US	5,856,096	08/514,921	14-Aug-95	Identification Of Two Novel Mutant Alleles Of Human Thiopurine S-Methyltransferase, And Diagnostic Uses Thereof
US	6,479,236	09/305,856	5-May-99	Genotyping the Human UDP-Glucuronosyltransferase 1 (UGT1) Gene
US	6,929,912	10/085,612	26-Feb-02	Method for Evaluating the Ability to Metabolize Pharmaceuticals and Compositions Therefor
US	7,250,258	11/005,029	7-Dec-04	CDK5 Genetic Markers Associated with Galantamine Response
US		61/410,735	5-Nov-10	PCR-PRIMERS AND METHODS FOR RAPID AND SPECIFIC GENOTYPING

Trademarks

COUNTRY	REGISTRATION NUMBER	APPLICATION NUMBER	DATE FILED	MARK / TITLE
CA	TMA646078	1226833	12-Aug-04	Familion
US	2965133	78385944	17-Mar-04	Familion
CA	TMA695396	1226832	12-Aug-04	Familion Logo
US	3007395	78389151	23-Mar-04	Familion Logo
US	3323112	77101247	2/7/07	PGXPREDICT
AU	934794	1201082	2/7/07	PGXPREDICT
CA		1357924	7/31/07	PGXPREDICT
EU	934794	934794	2/7/07	PGXPREDICT
WIPO	934794	934794	2/7/07	PGXPREDICT
JP	934794	934794	2/7/07	PGXPREDICT
US	3243160	78809592	2/8/2006	THERAPEUTIC DIAGNOSTICS
CA	760043	1312031	8/8/2006	THERAPEUTIC DIAGNOSTICS
EU	005245741	005245741	2/8/2006	THERAPEUTIC DIAGNOSTICS